Introduction
Obstructive sleep apnea syndrome (OSAS) causes sleep deprivation-induced symptoms (e.g., daytime sleepiness) and indirectly induces systemic symptoms, such as hypertension 1,2 and impaired glucose tolerance. 3, 4 Many studies have demonstrated that OSAS should be diagnosed and treated at an early stage, 5, 6 because OSAS can cause serious traffic accidents, 7 long-term hypoxic stress, 8 a pro-inflammatory state, 9 and endothelial dysfunction 10 in various organs. Although some patients with undiagnosed OSAS may visit an otolaryngology department to be treated for their snoring, other patients may visit a psychiatry department for a sense of malaise or a urology department for nocturia or erectile dysfunction. As OSAS generally induces vague and non-quantitative symptoms, it is difficult for patients and their doctors to determine that OSAS might be the cause of their symptoms. Therefore, it is likely that many people with OSAS remain undiagnosed. 11, 12 Nocturia is another multifactorial disorder that can be caused by hypertension, diabetes, heart failure, or sleeping disorders. 13, 14 OSAS can be an underlying cause of nocturia, although it is infrequently recognized, even in the field of urology. However, waking to urinate is an easily noticed and quantitative variable. Therefore, we hypothesized that its frequency could facilitate the early detection of OSAS in patients with frequent nocturia. The present study aimed to investigate the prevalence of nocturia among patients with newly diagnosed moderate-to-severe OSAS. We also assessed the correlation between various patient characteristics and urinary status, and evaluated the efficacy of continuous positive airway pressure (CPAP) for treating nocturia in patients with OSAS. Urinary status was assessed at baseline and three months after the CPAP treatment, using the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). 16 We also measured the number of nighttime urinations using Question 7 from the IPSS questionnaire; nocturia was defined as ≥2 urinations in a single night. Voiding status was calculated as the sum of the scores for Questions 1, 3, 5, and 6 from the IPSS questionnaire, and storage status was calculated as the sum of the scores from Questions 2, 4, and 7.
Patients were classified into three groups based their age and nocturia status. Group A included patients with nocturia who were <50 years old, Group B included patients with nocturia who were ≥50 years old, and Group C included patients who did not have nocturia (Fig. 1) . Using these groups, we assessed the association between OSAS severity and the patients' characteristics, as well as the efficacy of CPAP treatment for nocturia in each group.
Results were presented as mean ± standard deviation. Differences in nocturia and the IPSS voiding score (baseline vs. three months after CPAP treatment) were analyzed using the Wilcoxon-signed-ranks test, and differences in continuous characteristics were analyzed using the MannWhitney U-test. The correlation between nocturia status and the severity of OSAS was analyzed using Spearman's rank correlation test. All p values were two-sided and a p value of <0.05 was considered statistically significant. All analyses were performed using JMP software (version 10.0.2; SAS Institute, Irving, CA, U.S.).
Results

Urination status before CPAP treatment
The mean patient age was 53.8 years (range 21-83 years) and the mean body mass index (BMI) was 27.2 kg/m 2 (range 19.7-38.5 kg/m 2 ). Before the CPAP treatment, the average AHI was 47.7 ± 19.4 (range 17.7-99.0), 110 patients exhibited severe OSAS (an AHI of ≥30) and 28 patients exhibited moderate OSAS. The average number of nighttime urinations, total IPSS, and OABSS at baseline were 1.4 ± 1.3 (range 0-5), 6.0 ± 6.4 (range 0-34), and 2.7 ± 2.6 (range 0-13), respectively ( Table 1 ). The prevalence of nocturia was 40.6%; Group A included 40 patients, Group B included 16 patients, and Group C included 82 patients. Compared to patients with OSAS and without nocturia (Group C), patients with OSAS and nocturia (Groups A and B) tended to be significantly older (57.8 ± 12.3 years vs. 50.9 ± 11.9 years; p<0.01) and to have significantly more severe OSAS (AHI: 52.0 ± 19.1 vs. 44.7 ± 19.1; p=0.021) ( Table 2 ). The number of nighttime urinations was not correlated with OSAS severity in the entire patient population (correlation CPAP treatment affects urination in patients with OSAS coefficient: 0.104), although a significant correlation was observed among patients who were <50 years old (correlation coefficient: 0.343; p=0.013) (Fig. 2) . Furthermore, when we compared the patients with OSAS and nocturia, Group A exhibited a significantly higher AHI, compared to Group B (62.0 ± 18.9 vs. 47.8 ± 17.9; p=0.013). Moreover, patients in Group A did not exhibit additional urination symptoms, especially voiding symptoms (Table 2) .
Urination status after CPAP treatment
CPAP treatment significantly reduced the number of nighttime urinations (from 1.4 ± 1.3 to 0.7 ± 0.9; p<0.01), significantly improved the total IPSS (from 6.0 ± 6.4 to 4.3 ± 5.1; p<0.01), and significantly improved the total OABSS (from 2.7 ± 2.6 to 1.7 ± 1.7; p<0.01). Moreover, 50% fewer patients reported urgent incontinence after CPAP treatment (Table 1) . Among the 56 patients in Groups A and B, CPAP treatment significantly reduced the number of awakenings from 2.8 ± 0.9 times/night to 1.2 ± 1.1 times/night (p<0.01). After CPAP treatment, the number of urinations was reduced in 48 of the 56 patients (85.7%) with OSAS and nocturia before the CPAP treatment (12 patients in Group A [75%] and 36 patients in Group B [90%]). A significant difference was observed in the baseline OSAS severity when we compared patients with and without improved nocturia at three months after the CPAP treatment (AHI: 53.7 ± 18.6 vs. 37.3 ± 11.0; p=0.042).
Discussion
The present study revealed that nighttime urination was common among patients with OSAS and that patients with OSAS and nocturia tended to be older and have more severe OSAS (compared to patients with OSAS and without nocturia). The AHI was highest for <50-year-old patients with nocturia; these patients did not have additional urination symptoms, especially voiding symptoms. CPAP treatment decreased the incidence of nocturia in most patients and was most effective in patients with a severe AHI. Previous reports have indicated that the prevalence of nocturia among patients with OSAS (≥2 urinations per night) ranges from 40-50%. [17] [18] [19] The results of the present study are consistent with those findings and indicate that nocturia is a general symptom of moderate-to-severe OSAS. However, most patients (and even physicians) do not recognize the association between nocturia and OSAS. This lack of recognition is likely affected by the fact that nocturia is a common symptom among people ≥50 years old and is associated with a variety of clinical syndromes and diagnoses, including hypertension, diabetes, obesity, benign prostatic hyperplasia, and coronary artery disease. 13, 14 Oztura et al reported that nocturia episodes were significantly more frequent among patients with sleep-related breathing disorders. 20 Chen et al have also reported that nocturia is an independent predictor of severe obstructive sleep apnea in patients with ischemic stroke. 21 In contrast, we found that the number of nighttime urinations was not correlated with OSAS severity when we considered all patients in the present study. However, Kang et al have reported that age-related urinary diseases and voiding dysfunction may mask the influence of OSAS and that OSAS may not be a risk factor for nocturia among elderly patients. 22 Our data are consistent with that finding, as OSAS severity was correlated with the number of nighttime urinations among patients who were <50 years old. We also observed that nocturia in <50-year-old patients with OSAS was not accompanied by other voiding symptoms. Therefore, OSAS should be considered a potential cause of nocturia in younger patients who do not have other voiding symptoms.
An accurate diagnosis of OSAS requires laboratory PSG, which is inconvenient and costly. Therefore, clinicians must select patients for PSG testing according to their specific risk factors. However, the symptoms of OSAS (e.g., excessive daytime sleepiness and fatigue) are subjective, rather than quantitative, and are difficult to precisely evaluate or use to screen for OSAS. Therefore, various clinical prediction models and questionnaires have been developed for detecting OSAS. For example, the Epworth Sleep Scale (ESS) uses eight simple questions, is widely available, provides high reliability, and can be performed quickly and easily to subjectively measure sleepiness. Although there are suitable associations between ESS scores and the severity of OSAS, the ESS is not useful when screening for OSAS, as it is not sensitive or specific for this purpose. 23 Similarly, Morris et al reported that snoring severity and BMI are useful screening tools for OSAS, 24 although it is difficult for the patient or their sleeping partner to precisely evaluate the degree of snoring. In contrast, the number of nighttime urinations is a simple quantitative parameter that can be monitored by both urologists and general physicians. Therefore, we believe that nocturia might be a useful tool for screening patients with moderate-to-severe OSAS, especially patients who are <50 years old.
Nakagawa et al have reported that nocturia can lead to both bone fracture and death. 25 Moreover, treating nocturia is challenging and may result in only small improvements, as nocturia is a multifactorial condition. 26 However, our data indicate that CPAP treatment significantly reduced the number of nighttime urinations from 2.8 ± 0.9 to 1.2 ± 1.1 among patients with OSAS. Therefore, OSAS should be considered in the differential diagnosis of nocturia, as CPAP may effectively treat nocturia in patients with moderate-tosevere OSAS. Furthermore, CPAP treatment was effective in ameliorating other voiding symptoms (including urgent incontinence). Although the mechanism for this effect is unclear, improvements in hypoxic stress might positively affect the bladder's vascular endothelial cells.
There were several limitations in the present study. First, selection bias may have been introduced by selecting patients who visited a sleep clinic for OSAS treatment. Thus, prospective studies are needed to determine whether nocturia could be used to screen for OSAS in the general population. Second, the detailed mechanism for OSAS-induced nocturia is unclear, especially among patients who are <50 years old, although negative intrathoracic pressure can cause cardiac distention and the secretion of various vasodilators, which may increase urinary volume. Thus, future studies should incorporate frequency-volume charts, serum atrial natriuretic peptide levels, and the specific gravity of the morning urine before and after CPAP treatment, in order to better understand these patients' condition.
Conclusion
In <50-year-old patients with OSAS, the frequency of nocturia was correlated with the severity of OSAS and their nocturia was not accompanied by other voiding symptoms. CPAP treatment reduced the frequency of nocturia in patients with moderate-to-severe OSAS and this treatment may be most effective in patients with severe OSAS.
